Aliases & Classifications for Acute Mountain Sickness

MalaCards integrated aliases for Acute Mountain Sickness:

Name: Acute Mountain Sickness 53 73
High Altitude Pulmonary Edema 53 59 73
High Altitude Cerebral Edema 53 73
Altitude Sickness 53 73
Mountain Sickness 53 73
Altitude Anoxia 53

Characteristics:

Orphanet epidemiological data:

59
high altitude pulmonary edema
Prevalence: 1-9/1000000 (Europe);

Classifications:



External Ids:

Orphanet 59 ORPHA330012
ICD10 via Orphanet 34 J81
UMLS via Orphanet 74 C0340100

Summaries for Acute Mountain Sickness

MalaCards based summary : Acute Mountain Sickness, also known as high altitude pulmonary edema, is related to chronic mountain sickness and pulmonary edema, and has symptoms including apnea, cheyne-stokes respiration and coughing. An important gene associated with Acute Mountain Sickness is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and Pathways in cancer. The drugs Acetazolamide and Ibuprofen have been mentioned in the context of this disorder. Affiliated tissues include lung, endothelial and heart, and related phenotypes are cardiovascular system and behavior/neurological

Wikipedia : 76 Altitude sickness, also known as acute mountain sickness (AMS), is a negative health effect of high... more...

Related Diseases for Acute Mountain Sickness

Diseases in the Acute Mountain Sickness family:

Chronic Mountain Sickness

Diseases related to Acute Mountain Sickness via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 96)
# Related Disease Score Top Affiliating Genes
1 chronic mountain sickness 32.6 EDN1 NOS3 VEGFA
2 pulmonary edema 30.8 ACE EDN1 NOS3 PIK3C2A
3 hypoxia 30.1 EGLN1 HIF1A HIF1AN VEGFA VHL
4 pulmonary hypertension 29.2 ACE EDN1 FLT1 HIF1A NOS3 VEGFA
5 diabetes mellitus 29.1 ACE AGTR1 EDN1 NOS3 PIK3C2A VEGFA
6 pulmonary edema of mountaineers 11.2
7 unilateral absence of a pulmonary artery 11.1
8 acute anterolateral myocardial infarction 10.9 ACE PIK3C2A
9 hemifacial spasm 10.8 NOS3 VEGFA
10 virus associated hemophagocytic syndrome 10.8 MB PIK3C2A
11 intravascular papillary endothelial hyperplasia 10.7 HIF1A VEGFA
12 malignant triton tumor 10.7 MB S100B
13 intermediate coronary syndrome 10.7 ACE MB PIK3C2A
14 peripheral artery disease 10.7 ACE NOS3 VEGFA
15 pseudohyperkalemia, familial, 2, due to red cell leak 10.7 ACE MB PIK3C2A
16 interstitial myocarditis 10.7 MB PIK3C2A
17 angiokeratoma circumscriptum 10.6 FLT1 VEGFA
18 cerebritis 10.6
19 renal artery disease 10.6 ACE AGTR1 NOS3
20 hypertensive nephropathy 10.6 ACE AGTR1 VEGFA
21 critical limb ischemia 10.6 HIF1A VEGFA
22 pericardial effusion 10.6 HIF1A PIK3C2A VEGFA
23 diastolic heart failure 10.6 ACE AGTR1 NOS3
24 angina pectoris 10.5 ACE EDN1 NOS3
25 glomeruloid hemangioma 10.5 FLT1 VEGFA
26 sexual disorder 10.5 ACE EDN1 NOS3
27 mitral valve disease 10.5 ACE AGTR1 NOS3
28 hepatopulmonary syndrome 10.5 EDN1 NOS3 VEGFA
29 fiedler's myocarditis 10.5 ACE PIK3C2A
30 exudative vitreoretinopathy 1 10.5 FLT1 HIF1A VEGFA
31 microvascular complications of diabetes 5 10.4 ACE FLT1 NOS3 VEGFA
32 anuria 10.4 ACE AGTR1 MB PIK3C2A
33 large cell carcinoma with rhabdoid phenotype 10.4 ENO2 VEGFA
34 breast rhabdomyosarcoma 10.4 ENO2 MB
35 malignant hypertension 10.4 ACE AGTR1 EDN1
36 fumarate hydratase deficiency 10.4 HIF1A VHL
37 intracranial cysts 10.3 ENO2 S100B
38 renal hypertension 10.3 ACE AGTR1 EDN1
39 endotheliitis 10.3
40 bednar tumor 10.3 ENO2 S100B
41 headache 10.3
42 autosomal dominant polycystic kidney disease 10.3 ACE EDN1 NOS3 VEGFA
43 epithelioid hemangioendothelioma 10.3 FLT1 VEGFA VHL
44 renovascular hypertension 10.2 ACE AGTR1 EDN1 NOS3
45 ischemic optic neuropathy 10.2 ACE AGTR1 EDN1 NOS3
46 nonarteritic anterior ischemic optic neuropathy 10.2 ACE AGTR1 EDN1 NOS3
47 portal hypertension 10.1 AGTR1 EDN1 NOS3 VEGFA
48 von hippel-lindau syndrome 10.1 HIF1A VEGFA VHL
49 microcystic meningioma 10.1 ENO2 FLT1 VEGFA
50 cancer-associated retinopathy 10.1 ENO2 FLT1 VEGFA

Graphical network of the top 20 diseases related to Acute Mountain Sickness:



Diseases related to Acute Mountain Sickness

Symptoms & Phenotypes for Acute Mountain Sickness

UMLS symptoms related to Acute Mountain Sickness:


apnea, cheyne-stokes respiration, coughing, dyspnea, hoarseness

MGI Mouse Phenotypes related to Acute Mountain Sickness:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.38 HIF1AN FLT1 MB HIF1A NOS3 VEGFA
2 behavior/neurological MP:0005386 10.36 HIF1A ENO2 HIF1AN FLT1 S100B NOS3
3 cellular MP:0005384 10.34 EGLN1 HIF1A ENO2 HIF1AN FLT1 HSPA1B
4 homeostasis/metabolism MP:0005376 10.34 HIF1AN FLT1 MB HIF1A EGLN1 NOS3
5 growth/size/body region MP:0005378 10.32 HIF1A EGLN1 ENO2 HIF1AN FLT1 MB
6 hematopoietic system MP:0005397 10.23 EGLN1 HIF1A FLT1 NOS3 VEGFA PIK3C2A
7 endocrine/exocrine gland MP:0005379 10.15 HIF1A VEGFA NOS3 VHL ACE BDKRB2
8 immune system MP:0005387 10.14 EGLN1 HIF1A FLT1 VEGFA NOS3 PIK3C2A
9 embryo MP:0005380 10.11 EGLN1 HIF1A FLT1 MB VEGFA PIK3C2A
10 adipose tissue MP:0005375 10.1 HIF1AN NOS3 PIK3C2A ACE BDKRB2 ADRB2
11 muscle MP:0005369 10.02 EGLN1 HIF1AN FLT1 MB HIF1A NOS3
12 nervous system MP:0003631 10 EGLN1 HIF1A ENO2 FLT1 VEGFA NOS3
13 liver/biliary system MP:0005370 9.91 EGLN1 HIF1A HIF1AN VEGFA NOS3 VHL
14 normal MP:0002873 9.81 HIF1A HIF1AN FLT1 S100B VEGFA NOS3
15 renal/urinary system MP:0005367 9.7 HIF1A NOS3 VEGFA PIK3C2A VHL ACE
16 respiratory system MP:0005388 9.17 EGLN1 HIF1A ENO2 HIF1AN MB NOS3

Drugs & Therapeutics for Acute Mountain Sickness

Drugs for Acute Mountain Sickness (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetazolamide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-66-5 1986
2
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15687-27-1 3672
3
Methazolamide Approved Phase 4,Phase 1,Phase 2 554-57-4 4100
4
Nifedipine Approved Phase 4 21829-25-4 4485
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 50-02-2 5743
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
8
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
9
Acetylcysteine Approved, Investigational Phase 4,Phase 1,Phase 2 616-91-1 12035
10
Metformin Approved Phase 4 657-24-9 14219 4091
11
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
12 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Antioxidants Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
17 Protective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
18 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Sildenafil Citrate Phase 4 171599-83-0
22 Dexamethasone acetate Phase 4,Phase 1,Phase 2 1177-87-3
23 Epoetin alfa Phase 4 113427-24-0
24 calcium channel blockers Phase 4
25 diuretics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
26 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2
27
protease inhibitors Phase 4,Phase 1,Phase 2
28 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Chelating Agents Phase 4
30 Gastrointestinal Agents Phase 4,Phase 1,Phase 2,Not Applicable
31 Natriuretic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
32 Hematinics Phase 4,Not Applicable
33 Tocolytic Agents Phase 4,Phase 1
34 HIV Protease Inhibitors Phase 4,Phase 1,Phase 2
35 N-monoacetylcystine Phase 4,Phase 1,Phase 2
36 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
37 Hormones Phase 4,Phase 3,Phase 1,Phase 2
38 Angiotensin II Type 1 Receptor Blockers Phase 4
39 Angiotensin Receptor Antagonists Phase 4
40 Angiotensinogen Phase 4
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
42 Performance-Enhancing Substances Phase 4
43 Vasodilator Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Phosphodiesterase 5 Inhibitors Phase 4,Phase 1,Phase 2,Not Applicable
45 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
46 Antihypertensive Agents Phase 4,Phase 2,Phase 3,Phase 1
47 Anticoagulants Phase 4
48 Expectorants Phase 4,Phase 1,Phase 2
49 Anticonvulsants Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
50 Anti-Infective Agents Phase 4,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 110)
# Name Status NCT ID Phase Drugs
1 Erythropoietin in the Prevention of Acute Mountain Sickness Completed NCT01665781 Phase 4 Erythropoietin
2 A Trial of Acetazolamide Versus Placebo in Preventing Mountain Sickness During Rapid Ascent Completed NCT01418157 Phase 4 Acetazolamide;Placebo
3 Ibuprofen vs Acetaminophen for AMS Prevention Completed NCT02244437 Phase 4 Ibuprofen;Acetaminophen
4 Altitude Related Illness In Patients With Respiratory Disease Completed NCT02450968 Phase 4 Dexamethasone;Placebo
5 Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing Completed NCT01993667 Phase 4 Acetazolamide
6 Randomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness Completed NCT00627965 Phase 4 Sildenafil citrate;Placebo
7 Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude Completed NCT02024386 Phase 4 Riociguat
8 AZ, MZ, and the Pulmonary System Response to Hypoxia Completed NCT02760121 Phase 4 Acetazolamide;Methazolamide;Placebo
9 Treatment of High Altitude Polycythemia by Acetazolamide Completed NCT00424970 Phase 4 acetazolamide
10 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4 acetazolamide
11 Continuous Positive Airway Pressure and Acetazolamide to Treat Sleep Apnea Syndrome Patients at Altitude Completed NCT00928655 Phase 4 acetazolamide;placebo
12 HIGH Altitude CArdiovascular REsearch in the ANDES Completed NCT01830530 Phase 4 Telmisartan;Nifedipine;placebo
13 Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years Recruiting NCT03561675 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
14 Effect of Acetazolamide on Postural Control in Patients With Respiratory Disease at Altitude Recruiting NCT03177811 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
15 Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude Recruiting NCT03536429 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
16 Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude. Recruiting NCT03540914 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
17 Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude Recruiting NCT03539367 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
18 Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude Recruiting NCT03537924 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
19 Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude Recruiting NCT03536520 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
20 Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude Recruiting NCT03536455 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
21 Effect Of Acetazolamide On Altitude Related Illness In Patients With Respiratory Disease Recruiting NCT03156231 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
22 Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude Recruiting NCT03536507 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
23 Effect of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography Active, not recruiting NCT03490916 Phase 4 Acetazolamide;Placebo
24 Three New Ideas to Protect Special Forces From the Stress of High Altitude Active, not recruiting NCT02463357 Phase 4 Nifedipine extended release;Methazolamide;Metformin;Placebo;Nitrite
25 Induced Changes in Ventilatory Responsiveness and Altitude Exposure Terminated NCT01241513 Phase 4 NAC;Placebo
26 Altitude Sickness Prevention and Efficacy of Comparative Treatments Completed NCT02604173 Phase 3 Budesonide;Acetazolamide;Placebo
27 Anti-Oxidant Supplementation for the Prevention of Acute Mountain Sickness Completed NCT00664001 Phase 3
28 Drug Combination on Exercise Performance at High Altitude Completed NCT01902758 Phase 2, Phase 3 ambrisentan and theophylline;placebo
29 Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS) Completed NCT01171794 Phase 3 Ibuprofen;Placebo
30 Inhaled Budesonide for Altitude Illness Prevention Withdrawn NCT02941510 Phase 3 Budesonide
31 NSAID RCT for Prevention of Altitude Sickness Unknown status NCT01606527 Phase 2 Ibuprofen 600mg orally three times daily
32 Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness Unknown status NCT01682551 Phase 2 Chinese Medicine;Acetalozamide
33 Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness Completed NCT03270787 Phase 1, Phase 2 Placebo;Compound danshen dripping pills
34 Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness Completed NCT01536288 Phase 2 Rhodiola crenulata;placebo
35 Prevention of High Altitude Pulmonary Edema Completed NCT00274430 Phase 1, Phase 2 dexamethasone 8 mg bid;tadalafil 10mg bid
36 Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru Completed NCT01187108 Phase 1, Phase 2 N-acetylcysteine;Acetazolamide;Placebo pills
37 Rapid Acclimatization to Hypoxia at Altitude Completed NCT01702025 Phase 1, Phase 2 Placebo;Aminophylline;Methazolamide;Aminophylline+Methazolamide
38 Evaluation of the Attenuation by Aes-103 of Hypoxia Mediated Decrements in Endurance Exercise Performance Completed NCT01871142 Phase 1, Phase 2 Placebo;Aes-103;Aes-103
39 Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS) Not yet recruiting NCT03552263 Phase 2 T89 capsule;Placebo capsule
40 Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDS) on Acclimatization to High Altitude Unknown status NCT02233582 Phase 1 Ibuprofen
41 Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy Completed NCT03154645 Phase 1 Ibuprofen;Acetazolamide
42 Inhaled Budesonide and Acute Mountain Sickness Completed NCT02811016 Phase 1 Budesonide 200;Budesonide 800;Placebo
43 A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude Completed NCT01794078 Phase 1 Aminophylline 400 mg;Ambrisentan 5 mg
44 Safety Evaluation of Aminophylline and Methazolamide Completed NCT01587027 Phase 1 Aminophylline;Methazolamide;Aminophylline and Methazolamide
45 Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia Completed NCT00260819 Phase 1 Bosentan;Bosentam TRACLEER
46 Hypoxia Impairs Endothelial Function in HAPEs Completed NCT00176007 Phase 1
47 A Clinical Trial of the Clinical Effects of Hyperbaric Oxygen Therapy in Thai Autistic Children Completed NCT00670891 Phase 1
48 The Safety Evaluation of Drug Combinations Against High Altitude Pulmonary Hypertension Completed NCT01566565 Phase 1 Theophylline and Bambuterol
49 The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers Completed NCT01530464 Phase 1 Aminophylline;Ambrisentan;Aminophylline plus ambrisentan
50 Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages Recruiting NCT03424226 Phase 1 Acetazolamide

Search NIH Clinical Center for Acute Mountain Sickness

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Acute Mountain Sickness

Anatomical Context for Acute Mountain Sickness

MalaCards organs/tissues related to Acute Mountain Sickness:

41
Lung, Endothelial, Heart, Testes, Brain, Skeletal Muscle, Pituitary

Publications for Acute Mountain Sickness

Articles related to Acute Mountain Sickness:

(show top 50) (show all 708)
# Title Authors Year
1
Elevated Vasodilatory Cyclases and Shorter Telomere Length Contribute to High-Altitude Pulmonary Edema. ( 29443612 )
2018
2
Diagnosing Acute Mountain Sickness-Reply. ( 29634826 )
2018
3
Electronic Nose Technology Fails to Sniff Out Acute Mountain Sickness. ( 29641295 )
2018
4
Increased Cytokines at High Altitude: Lack of Effect of Ibuprofen on Acute Mountain Sickness, Physiological Variables, or Cytokine Levels. ( 29924642 )
2018
5
Impact of Sleeping Altitude on Symptoms of Acute Mountain Sickness on Mt. Fuji. ( 29741971 )
2018
6
Optic nerve oedema at high altitude occurs independent of acute mountain sickness. ( 29973364 )
2018
7
The 2018 Lake Louise Acute Mountain Sickness Score. ( 29583031 )
2018
8
Diagnosing Acute Mountain Sickness. ( 29634823 )
2018
9
Sequencing the exons of human glucocorticoid receptor (NR3C1) gene in Han Chinese with high-altitude pulmonary edema. ( 29587872 )
2018
10
Plasma proteomic study of acute mountain sickness susceptible and resistant individuals. ( 29352170 )
2018
11
Efficacy of Dexamethasone in Preventing Acute Mountain Sickness in COPD Patients: Randomized Trial. ( 29909285 )
2018
12
Exploration of Acute Phase Proteins and Inflammatory Cytokines in Early Stage Diagnosis of Acute Mountain Sickness. ( 29608374 )
2018
13
The relationship between anxiety and acute mountain sickness. ( 29927953 )
2018
14
Single Question Is Useful for Identifying Acute Mountain Sickness in Travelers at High Altitude. ( 29763259 )
2018
15
Pharmacological interventions for preventing acute mountain sickness: a network meta-analysis and trial sequential analysis of randomized clinical trials. ( 29166795 )
2018
16
Association between acute mountain sickness (AMS) and age: a meta-analysis. ( 29747689 )
2018
17
HMOX1 Promoter Microsatellite Polymorphism and High Altitude Pulmonary Edema in Han Chinese Men. ( 29398188 )
2018
18
Transcriptomic profiling reveals gene expression kinetics in patients with hypoxia and high altitude pulmonary edema. ( 29366758 )
2018
19
Relationship between Smoking and Acute Mountain Sickness: A Meta-Analysis of Observational Studies. ( 29259975 )
2017
20
Unilateral High-Altitude Pulmonary Edema. ( 28837778 )
2017
21
Remote ischemic preconditioning does not prevent acute mountain sickness after rapid ascent to 3450 m. ( 28798201 )
2017
22
Acute mountain sickness amongst tourists to Lhasa. ( 28149514 )
2017
23
A Signature of Circulating microRNAs Predicts the Susceptibility of Acute Mountain Sickness. ( 28228730 )
2017
24
Acute Mountain Sickness. ( 29136446 )
2017
25
Acute mountain sickness, arterial oxygen saturation and heart rate among Tibetan students who reascend to Lhasa after 7 years at low altitude: a prospective cohort study. ( 28698346 )
2017
26
Reentry High Altitude Pulmonary Edema in the Himalayas. ( 28910201 )
2017
27
Smartphone-Enabled Heart Rate Variability and Acute Mountain Sickness. ( 28407652 )
2017
28
Does This Patient Have Acute Mountain Sickness?: The Rational Clinical Examination Systematic Review. ( 29136449 )
2017
29
IL-10 Dysregulation in Acute Mountain Sickness Revealed by Transcriptome Analysis. ( 28611780 )
2017
30
Dietary nitrate supplementation increases acute mountain sickness severity and sense of effort during hypoxic exercise. ( 28684588 )
2017
31
High-Altitude Pulmonary Edema in Mountain Community Residents. ( 28846035 )
2017
32
Budesonide Versus Acetazolamide for Prevention of Acute Mountain Sickness. ( 28668540 )
2017
33
Inhaled budesonide does not prevent acute mountain sickness after rapid ascent to 4559a88m. ( 28890439 )
2017
34
MEDEX2015: Greater Sea-Level Fitness Is Associated with Lower Sense of Effort During Himalayan Trekking Without Worse Acute Mountain Sickness. ( 28394182 )
2017
35
MEDEX 2015: Heart Rate Variability Predicts Development of Acute Mountain Sickness. ( 28418725 )
2017
36
Prophylactic Acetaminophen or Ibuprofen Result in Equivalent Acute Mountain Sickness Incidence at High Altitude: A Prospective Randomized Trial. ( 28479001 )
2017
37
Susceptibility To High Altitude Pulmonary Edema Is Associated With A More Uniform Distribution Of Regional Specific Ventilation. ( 28057815 )
2017
38
Effects of rapid ascent on the heart rate variability of individuals with and without acute mountain sickness. ( 28251400 )
2017
39
HMOX1 Promoter Microsatellite Polymorphism Is Not Associated With High Altitude Pulmonary Edema in Han Chinese. ( 28257713 )
2017
40
Response to letter to the editor regarding "Acute mountain sickness among tourists visiting the high-altitude city of Lhasa, Tibet, China at 3658A m above sea level: a cross-sectional study". ( 28469847 )
2017
41
Incidence and severity of acute mountain sickness and associated symptoms in children trekking on Xue Mountain, Taiwan. ( 28832689 )
2017
42
Heterogeneous regulation of cerebral blood flow in hypoxia; implications for dynamic cerebral autoregulation and susceptibility to acute mountain sickness. ( 28247477 )
2017
43
Inhaled budesonide for acute mountain sickness. ( 28890440 )
2017
44
Findings of Cognitive Impairment at High Altitude: Relationships to Acetazolamide Use and Acute Mountain Sickness. ( 28509579 )
2017
45
Wearable Physiologic Sensors and Real-Time Algorithms for Detection of Acute Mountain Sickness. ( 29074708 )
2017
46
Electron Microscopy Observation of Human Pulmonary Ultrastructure in Two Patients with High-Altitude Pulmonary Edema. ( 28876136 )
2017
47
Is acute mountain sickness related to trait anxiety? A normobaric chamber study. ( 28069461 )
2017
48
Residence at Moderate Versus Low Altitude Is Effective at Maintaining Higher Oxygen Saturation During Exercise and Reducing Acute Mountain Sickness Following Fast Ascent to 4559 m. ( 28455198 )
2017
49
Soluble Urokinase-Type Plasminogen Activator Receptor Plasma Concentration May Predict Susceptibility to High Altitude Pulmonary Edema. ( 27378823 )
2016
50
ROCK2 and MYLK variants and high-altitude pulmonary edema. ( 27536156 )
2016

Variations for Acute Mountain Sickness

Expression for Acute Mountain Sickness

Search GEO for disease gene expression data for Acute Mountain Sickness.

Pathways for Acute Mountain Sickness

Pathways related to Acute Mountain Sickness according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.04 EGLN1 HIF1A HIF1AN HSPA1A HSPA1B VEGFA
2 12.73 AGTR1 BDKRB2 EGLN1 HIF1A VEGFA VHL
3
Show member pathways
12.35 EGLN1 HIF1A VEGFA VHL
4
Show member pathways
12.14 ADRB2 AGTR1 BDKRB2 NOS3
5
Show member pathways
12.11 FLT1 NOS3 PIK3C2A VEGFA
6 11.81 AGTR1 EDN1 NOS3 VEGFA
7
Show member pathways
11.77 FLT1 HIF1A NOS3 VEGFA VHL
8 11.72 EGLN1 FLT1 HIF1A HIF1AN NOS3
9
Show member pathways
11.7 ACE AGTR1 BDKRB2 NOS3
10
Show member pathways
11.69 FLT1 NOS3 PIK3C2A
11 11.57 ACE ADRB2 AGTR1
12 11.57 EDN1 EGLN1 HIF1A VEGFA
13 11.56 EDN1 EGLN1 ENO2 FLT1 HIF1A NOS3
14
Show member pathways
11.52 HSPA1A HSPA1B NOS3
15 11.22 EDN1 EGLN1 HIF1A HIF1AN VEGFA
16
Show member pathways
11.18 EDN1 HIF1A VEGFA
17 11.09 EGLN1 FLT1 HIF1AN VEGFA VHL
18 11.01 EDN1 EGLN1 HIF1A HIF1AN HSPA1A HSPA1B
19 11 FLT1 HIF1A NOS3 VEGFA
20 10.83 HIF1A HIF1AN VHL
21
Show member pathways
10.82 FLT1 VEGFA
22 10.56 HIF1A HIF1AN VEGFA
23 10.49 MB NOS3

GO Terms for Acute Mountain Sickness

Cellular components related to Acute Mountain Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.47 ACE EDN1 EGLN1 ENO2 FLT1 HIF1A

Biological processes related to Acute Mountain Sickness according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.97 FLT1 HIF1A HSPA1A HSPA1B VEGFA VHL
2 angiogenesis GO:0001525 9.93 FLT1 HIF1A NOS3 VEGFA
3 positive regulation of angiogenesis GO:0045766 9.84 FLT1 HIF1A NOS3 VEGFA
4 regulation of blood pressure GO:0008217 9.8 ACE EDN1 NOS3
5 positive regulation of MAP kinase activity GO:0043406 9.79 EDN1 FLT1 VEGFA
6 positive regulation of blood vessel endothelial cell migration GO:0043536 9.74 HIF1A NOS3 VEGFA
7 cellular response to hypoxia GO:0071456 9.73 EDN1 HIF1A S100B VEGFA
8 regulation of protein ubiquitination GO:0031396 9.65 HSPA1A HSPA1B
9 regulation of cell death GO:0010941 9.64 HSPA1A HSPA1B
10 negative regulation of inclusion body assembly GO:0090084 9.63 HSPA1A HSPA1B
11 positive regulation of erythrocyte differentiation GO:0045648 9.63 HIF1A HSPA1A HSPA1B
12 positive regulation of tumor necrosis factor-mediated signaling pathway GO:1903265 9.62 HSPA1A HSPA1B
13 oxygen homeostasis GO:0032364 9.61 EGLN1 HIF1A
14 positive regulation of receptor biosynthetic process GO:0010870 9.6 EDN1 HIF1A
15 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.59 ACE AGTR1
16 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.58 EDN1 NOS3
17 cellular heat acclimation GO:0070370 9.58 HSPA1A HSPA1B
18 blood vessel morphogenesis GO:0048514 9.58 EDN1 FLT1 HIF1A
19 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.56 HIF1A VEGFA
20 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.55 ACE VEGFA
21 response to hypoxia GO:0001666 9.55 EDN1 EGLN1 HIF1A MB VEGFA
22 negative regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061428 9.52 HIF1AN VHL
23 positive regulation of microtubule nucleation GO:0090063 9.51 HSPA1A HSPA1B
24 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.5 FLT1 HIF1A VEGFA
25 positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway GO:0070434 9.48 HSPA1A HSPA1B
26 regulation of blood vessel diameter GO:0097746 9.43 ACE ADRB2 AGTR1
27 positive regulation of chemokine-mediated signaling pathway GO:0070101 9.37 EDN1 HIF1A
28 regulation of vasoconstriction GO:0019229 9.26 ACE AGTR1 BDKRB2 EDN1
29 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.02 EGLN1 HIF1A HIF1AN VEGFA VHL
30 positive regulation of cell proliferation GO:0008284 10.04 CCK EDN1 FLT1 S100B VEGFA

Molecular functions related to Acute Mountain Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors GO:0016706 9.26 EGLN1 HIF1AN
2 C3HC4-type RING finger domain binding GO:0055131 9.16 HSPA1A HSPA1B
3 enzyme binding GO:0019899 9.1 ADRB2 EGLN1 HIF1A HSPA1A HSPA1B VHL
4 bradykinin receptor binding GO:0031711 8.96 ACE AGTR1

Sources for Acute Mountain Sickness

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....